中国血液净化

中国血液净化 ›› 2018, Vol. 17 ›› Issue (01): 9-12.doi: 10.3969/j.issn.1671-4091.2018.01.003

• 专题 • 上一篇    下一篇

不同透析中心之间ESA 剂量差异的原因分析

梁献慧1,刘章锁1   

  1. 1. 郑州大学第一附属医院血液净化中心肾脏内科
  • 收稿日期:2017-06-09 修回日期:2017-07-03 出版日期:2018-01-12 发布日期:2018-01-12
  • 通讯作者: 刘章锁 zhangsuoliu@sina.com.cn E-mail:zhangsuoliu@sina.com.cn

Studies on the dosage variation of erythrocyte-forming stimulant agents (ESAs) in different dialysis centers

,   

  • Received:2017-06-09 Revised:2017-07-03 Online:2018-01-12 Published:2018-01-12

PDF

548

摘要： 红细胞生成刺激剂(erythrocyte-forming stimulants, ESA)为临床上常用的治疗肾性贫血的药物，近年来ESA 的使用剂量有着显著的变化，研究发现不同透析中心ESA 的使用剂量有显著差异，且ESA 高剂量应用者的全因死亡风险升高。本文从患者基线状况、ESA 反应性以及临床需要方面方面对使用ESA的剂量差异原因作了简要分析。

关键词: 红细胞生成刺激剂, 透析充分性, 铁调素, 矿物质及骨异常

Abstract: Erythrocyte-forming stimulant agents (ESAs) are widely used in the treatment of renal anemia. Recently, the dosage of ESAs is changed dramatically and is varied in different dialysis centers. However, higher dosage of ESAs will raise the all-cause death risk. This article analyzes the cause of ESAs dosage
variation focused in the baseline characteristics of patients, reactivity to ESAs and clinical needs.

Key words: Erythrocyte-forming stimulants (ESA), Adequacy of dialysis, Hepcidin, Mineral and Bone disorder